ABOUT
US BIOLOGIC Delivers Disease Prevention®.
US BIOLOGIC develops groundbreaking orally delivered vaccines, changing global disease prevention and allowing safe, effective, and cost-efficient delivery of preventative interventions to wildlife, companion animals, food animals, and humans.
We work with world-renowned experts, placing their proven technologies into our oral-delivery platform. We then commercialize those new products by providing necessary funding, regulatory support, manufacturing, and distribution expertise.
LEADERSHIP
Executive & Science Leadership
Chief Executive Officer, Board Chairman
Chief Executive Officer, Board Chairman
Kauffman received his BS from the University of Michigan and MBA from the University of Memphis. He was part of FedEx’s pioneering teams from 1978-1994 before leaving to found, grow, and sell his own businesses. Those companies, Express Logistics and Accuship, earned Inc. Magazine’s 500 Fastest Growing Company status. Kauffman was recognized as Entrepreneur of the Year by Ernst & Young, as an industry “mover and shaker” by Bloomberg Businessweek, and as a “leader in the pack” by LEADERS Magazine.
President, Board Secretary
President, Board Secretary
Przybyszewski earned his BA from the University of Pennsylvania and his MA from the University of Memphis. In his career, he has built large-scale, public/private programs, particularly in the public healthcare space and has founded or co-founded several companies, including a mobile application company (later acquired). He also has helped create founding and growth strategies, earn funding (e.g., investment, grants, contracts, and revenue-generating programs), build B2B joint-business ventures, co-author journal and patent publications, earn media, and stimulate company growth.
Chief Scientific Officer
Chief Scientific Officer
Dr. van Oosterwijk received her BSc degree from the University College Utrecht in pre-med and medicinal chemistry, MSc degree in Molecular Medicine from the Charité Medical School in Berlin, and her PhD in Translational Science/Oncology from the Leiden University Medical Centre. After earning her PhD, she functioned as a Postdoctoral Research Associate at St. Jude Children’s Research Hospital in pharmaceutical sciences and then transitioned to working as a Research Associate at the Howard Hughes Medical Institute in tumor cell biology. At US BIOLOGIC, Dr. van Oosterwijk leads all development of US BIOLOGIC’s OrisBio platform, including orally delivered antimicrobials and vaccines for animals and humans. Most recently, she is leading development of a novel chewable vaccine to reduce pandemic influenza.
Chief Operating Officer
Chief Operating Officer
Roan earned his BS in Mechanical Engineering from Tennessee Technological University and an MBA from the University of Memphis. He has extensive experience in strategy, operations, and new product innovation, bridging the gap between product development, operations, and commercialization. Before joining US Biologic, Roan led R&D for Smith & Nephew’s orthopedic $650M hip franchise and lead cross functional teams to ideate, develop, and launch multiple large-scale orthopedic hip and knee platforms. He has led large-scale regulatory initiatives, global product data standardization, and change management programs. Early in his career, he gained deep expertise in lean product development and manufacturing at Toyota, experience that continues to shape his approach to operational excellence.
Chief Commercial Officer
Chief Commercial Officer
Good received his BA in Economics from the University of Memphis and has since become one of the pest-management industry’s leading marketing and sales executives with a focus on bringing new products to market, expanding national markets, and M&A activities. In his executive leadership roles at Terminix, Good provided sales leadership, business strategy development, brand positioning, direct marketing, media advertising, public relations, promotions, and product placement across multiple verticals.
Good oversaw the successful integration of these business development strategies to help propel Terminix to their industry leadership position while overseeing a $60M annual marketing budget, managing a global sales force of over 1,500, and generating over $500,000,000 in annualized sales.
Vice President of Manufacturing
Vice President of Manufacturing
Dr. Zatechka earned his PhD from the University of Nebraska Medical Center and his MBA from the University of Memphis. He completed his postdoctoral fellowship with the Howard Hughes Medical Institute at St. Jude Children’s Research Hospital. Dr. Zatechka is experienced in the development and utilization of gene targeting technologies for animal models and the development of applied biotechnology-based protocols. Dr. Zatechka is the inventor of US BIOLOGIC’s patented production platform technology.
Vice President of Regulatory & Quality
Vice President of Regulatory and Quality
Dr. Brooke received a Master of Public Health from the Vrije Universiteit Amsterdam and a PhD in Clinical Epidemiology from Utrecht University. He has worked with National and International public health departments in Europe and the U.S. on seroprevalence, notifiable infectious diseases, human dose-response models, and geospatial trends of zoonotic infection pressure combining clinical trial data, real-world data, and big data. He then worked in pharmacogenomics survivorship at St. Jude Children's Research Hospital using whole-genome sequencing to develop analytics pipelines. Recently, he transitioned into the medical-device industry working for Smith&Nephew where he planned and executed the creation of an Artificial Intelligence Center of Excellence to help the 150-year-old company transition into the digital age. Dr. Brooke has advised several companies with regard to their digital health strategy and enjoys making corporate vision into reality. He has 19 publications, three patents, and two invention disclosures.
Senior Science Advisor
Senior Science Advisor
Dr. Wikel received a Ph.D. from the University of Saskatchewan and went on to serve as a staff fellow at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, as well as Professor and Acting Chair, Department of Immunology, School of Medicine, University of Connecticut. He subsequently served as Professor of Pathology, University of Texas Medical Branch and Senior Scientist at the Center for Tropical Diseases and Center for Biodefense and Emerging Infectious Diseases, Galveston National Laboratory.
In 2011, Dr. Wikel was appointed Senior Associate Dean, Professor and Chairman, Department of Medical Sciences, and St. Vincent’s Medical Center Endowed Chair, School of Medicine, Quinnipiac University, as one of four deans to establish a new school.
Dr. Wikel has led worldwide research collaborations in tick physiology and genetic discovery research, as well as host immunological responses and vector countermeasures to host defenses at the arthropod vector-host-pathogen interface; the role of those interactions on blood feeding and pathogen transmission; and, development of novel immune-based anti-vector and pathogen transmission blocking control strategies.
Dr. Wikel has ninety-one peer reviewed publications and sixteen invited review and book chapters on these topics. He has been a featured speaker for seventy-five national and international symposia. Dr. Wikel received extramural research support for his program from the National Institutes of Health, U.S. Army Medical Research and Materiel Command, Centers for Disease Control and Prevention, U.S. Department of Agriculture and industry. He has extensive service experience as a member of advisory panels, research study sections, editorial boards and academic institution administration.
Process Engineer
Process Engineer
Ian Johnson received his BS in Biomedical Engineering from the University of Memphis. He has developed new products with an expertise in 3-D printing, as well as the design and execution of formulation studies for new orally delivered vaccines. At US BIOLOGIC, Ian provides laboratory and technical support.
Research Technician
Research Technician
Argerie Marin received her BS in Microbiology from Mississippi State University. She most recently served as a molecular technologist and COVID Accessioner, leading efforts to design and carryout high throughput testing of new COVID diagnostic tools. At US BIOLOGIC, Argerie supports all laboratory activities.
Board of Directors
Board Member
Meccia has enjoyed over 38 years of domestic and international experience leading sales, marketing, manufacturing and technical teams. He currently serves as Chairman and CEO of Gluon Chemical, a specialty chemical company serving the paper and packaging industry. Previously, John was President, CEO and Chairman of Prevenio, a food safety business that he grew from startup to successful integration with JBT Corporation in 2021 after a $175 million exit.
Earlier in his career, John served as Global Vice President of paper converting and graphic arts for Henkel Corporation, one of the world's largest chemical companies. He has also directed the North American paper packaging business and created a startup service consultancy division for National Starch & Chemical before its sale to Henkel. John graduated from the University of Illinois in 1986 with a B.S. in Chemical Engineering.
Board Member, Retired Director, CDC Retired Chief, USAMRIID
Dr. Monath received his AB degree from Harvard College and his MD from Harvard Medical School and is board certified in internal medicine and is an internationally recognized virologist and vaccinologist with over 50 years’ experience in research on viral and bacterial diseases, 25 of which have been in the vaccines industry. His expertise spans discovery research and all functional areas of product development. He has worked in leadership positions in US government agencies and in the biotechnology sector. He had primary responsibility for bringing multiple innovative vaccines into clinical development, including Ebola Zaire, cell based smallpox, dengue, Japanese encephalitis, West Nile, cytomegalovirus, influenza, live and inactivated yellow fever, Helicobacter pylori, Clostridium difficile , four of which are now licensed and commercialized.
Before forming Crozet, Dr. Monath was CSO and COO of BioProtection Systems, the infectious disease subsidiary of NewLink Genetics, where he led the development of the recombinant vesicular stomatitis vectored Ebola vaccine funded by BARDA and DTRA in partnership with Merck, and he initiated and led development efforts on a new Zika vaccine.
Prior thereto, he was Chief Medical Officer of Hookipa Biotech, Juvaris and Xcellerex and between 1992 and 2006, he was CSO and an Executive Director of Acambis before its acquisition by Sanofi Pasteur. In that position he developed a novel platform for vaccine development (ChimeriVax™), and brought 3 human and 1 veterinary vaccine through regulatory approval, including ACAM2000® smallpox vaccine under $500m development and procurement contracts from HHS.
Along with US BIOLOGIC, Dr. Monath serves on the boards of Juvaris Inc. and Sentinext Plc and on the Scientific Advisory Boards of RapidMicro Biosystems, GeoVax and SutroVax. Between 2006-1012, Dr. Monath was a Partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm where oversaw investments in the vaccine space. Before joining industry, Dr. Monath served in the uniformed services of US Public Health Service and the US Army for 24 years, retiring as a Colonel. During that time he was Director, Division of Vector-Borne Viral Diseases at the Centers for Disease Control and Prevention (CDC) and Chief, Virology Division at the US Army Medical Research Institute of Infectious Diseases (USAMRIID).
He has received many prestigious awards, including the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), the Walter Reed Medal (2002) and the James H. Steele Gold-Headed Cane Award (2015). He has served on numerous government and international committees on infectious diseases, biosecurity, WHO expert committees and the National Vaccines Advisory Committee (USA), and is Past-President of the American Society of Tropical Medicine and Hygiene and an elected Fellow of the Society. He has been a leader in and founding member of the One Health Initiative and is an expert in arthropod-borne viruses. He has published over 425 scientific papers and 6 books on virology and vaccine development and has 35 patents.
Board Member, Chairman of Clearbrook Holdings, LLC
Shmerling received his Bachelor of Accountancy degree from the University of Oklahoma and is a veteran entrepreneur who has established and grown profitable companies in a wide spectrum of industries, including finance, consumer products, and corrections, among others.
Shmerling began his career as a CPA with Ernst & Young and has since founded five businesses, four of which were acquired by publicly traded companies. At present, Shmerling serves as Chairman of Clearbrook Holdings Corp., a management and investment holding company. In addition, Shmerling serves on the board of several companies including Choice Food Group, Inc., Maynard Select, LLC, and Health Connect America, Inc. In 2007, he was awarded the American Institute of CPA’s Public Service Award.
Board Member, Emeritus WI Governor for 14 years Secretary, U.S. DHHS
Gov. Thompson served as Wisconsin’s governor for fourteen years, focusing on the revitalization of the state’s economy. Through these efforts, Gov. Thompson gained national attention for his leadership on welfare reform, expanding access to health care for low-income people, and education. In 2001, Gov. Thompson accepted the nomination for U.S. Secretary of Health and Human Services. As the nation’s leading advocate for the health and welfare of all Americans, Gov. Thompson led the department which employed more than 60,000 personnel and had a fiscal year 2001 budget of $429 billion. In July 2020, Gov. Thompson became the interim president of the University of Wisconsin System.
Board Member, Emeritus, Retired Chairman, CEO, and President of Sanofi Pasteur, Inc.
Williams holds a degree in Accounting and Management from Scranton University and retired in 2008 as Chairman & CEO of Sanofi Pasteur, the vaccines business of Sanofi-Aventis Group. Williams’ thirty years with the company was marked by his rise from Finance Manager, to General Manager of the U.S. Business unit, to being named the company’s U.S. President of the company. He was later named Global President & COO in 1998. Williams’ leadership moved the company from a niche vaccine business to the global leader in vaccine development, production, and sales, with 2007 revenues of more than U.S. $6 billion. Sanofi Pasteur is the largest vaccine business in the world and but also provides the broadest range of vaccines available from a single company.
Under Williams’ guidance, more than one billion doses of Sanofi Pasteur’s lifesaving vaccines were administered to more than 500 million people around the world each year, representing more than 25% of the global vaccine market. The company grew to almost 13,000 employees, licensed more than 30 new vaccines and launched hundreds of business development programs under Williams’ leadership.
Senior Advisors
Inventor
Inventor
Dr. Gomes-Solecki earned her DVM from the University of Lisbon, completed a Fellowship at the National Institute of Technology, Lisbon, Portugal, and her post-doctorate work at Stony Brook University.
She is now an Associate Professor of Microbiology and Immunology, University of Tennessee Health Science Center, serves as president of Immuno Technologies, and is the inventor of US BIOLOGIC’s first oral vaccination technology. In 2014, Dr. Gomes-Solecki was recognized as the “Innovator of the Year” by MBQ Magazine.
Senior Political Advisor
Senior Political Advisor
Mr. Kaufman has Master Degrees in both Biology and Public Administration, from St. John’s University and New York University, respectively. He has over twenty years’ experience leading the State Government Affairs function at Sanofi Pasteur, the vaccine subsidiary of Sanofi Aventis. Over that time, Kaufman led lobbying and public policy initiatives in over 40 states and interacted with major policy organizations in the public health arena. Sanford advises US BIOLOGIC management and board leaders on all state efforts, helps coordinate lobbyist activities, and ensure full compliance with all state lobbyist regulations.
Senior Production Advisor
Senior Production Advisor
Daryl is an animal health industry veteran and former CEO of Ceva Biomune, a division of CEVA Sante Animale, where he oversaw all biologics research and development, regulatory affairs and compliance, production, and all support-related functions for their 400-employee, 300,000 sq. ft. production and warehouse operations. Prior to Ceva, Daryl was Senior Manager of Technical Operations for Novartis Animal Health and Director at Wyeth/Fort Dodge Animal Health.
Daryl has a diverse hands-on experience in biological and pharmaceutical industries and in all phases of operations management including bioreactor, research & development, downstream processing, sterile filling, product development, inventory and capacity planning, facility capital and manufacturing budgets, P&L, purchasing, warehouse control, technology implementation, Lean, 5S, Theory of Constraints, overall equipment effectiveness, facility consolidations and closures, bargaining unit negotiations, USDA (9-CFR), CFIA, FDA (21-CFR) and European Communities Veterinary Medicines Directorate (VMD) GMP compliance.
Senior Political Advisor
Political Advisor
Receiving his BA degree from Trinity University and his JD degree from Tulane University School of Law, Gen. Suter has served in numerous positions of responsibility around the world, including Appellate Judge, Deputy Staff Judge Advocate of the U.S. Army Vietnam, Staff Judge Advocate of the 101st Airborne Division, Commandant of the JAG School, and the Assistant Judge Advocate General of the Army.
Most recently, Gen. Suter has recently retired as the 19th Clerk of the Supreme Court of the U.S. where he served for twenty-two years. Gen. Suter also served as Army Judge Advocate before retiring as a Major General. Gen. Suter provides US BIOLOGIC with governmental agency and military leadership insights and guidance.
Advisor
Advisor, CIO and Sr Managing Partner with WP Global Partners LLC
Mr. Oberholtzer received his B.B.A. from George Washington University. Mr. Oberholtzer is the co-founder of a multi-billion dollar registered private markets investment firm, focused on established and growth companies. He has 38 years of investment advisory experience in alternative investments. He actively manages private investments across industries sectors and product stages, and served on more the board of more than a dozen company boards. As an active investor, Mr. Oberholtzer provides operating and strategic guidance as a board member or observer. Prior to WP Global, he was a Director of WestAM where he was responsible for their small and middle market buyouts, special situations and co-investments and was a member of the private equity executive committee and investment committee. Prior to WestAM, Mr. Oberholtzer was a Managing Director with Forstmann-Leff International (“FLI”) and a Director at Jefferies Group, where he was involved in product structure and fund management in equities and listed derivatives. His investment experience includes Chase Manhattan Bank, Dominick & Dominick and E.F. Hutton. Mr. Oberholtzer has served as the president of two private financial services companies and was active in a successful family business for several years.
Senior Political Advisor
Senior Political Advisor
Komorous holds an MS in National Security & Resource Strategy from the Eisenhower School at National Defense University, is an MIT Chapter 21 Fellow, and a Wharton Public Policy Fellow. As the former Legislative Affairs Special Assistant for Acquisitions & Sustainment within the Office of the Assistant Secretary of Defense, Komorous developed critical expertise in bridging Department of Defense priorities with Congressional funding mechanisms, particularly for innovative health security technologies.
As the former Senior Air Force Advisor for Strategy and Force Development, Mike helped develop the Defense Planning Guidance with a focus on public health security initiatives that protect force readiness. His public health security expertise makes him uniquely qualified to position innovative vector-borne disease prevention technologies as critical components of the DoD's integrated health protection strategy for military installations in high-risk regions.
His distinguished military career earned him numerous awards including the Legion of Merit.
USDA/CVB Consultant
USDA/CVB Consultant
Dr. McCauley is a three-time graduate of Texas A&M University and a member of the DVM Class of 2012. After completing a rotating clinical internship at Carolina Veterinary Specialists in Charlotte, NC, Dr. McCauley practiced small animal and exotic medicine in Dallas, TX. He most recently served as Director of Veterinary Biologics at the Animal Health Institute, a Washington, D.C.-based trade association representing the manufacturers of animal health products in the United States. He now serves a variety of companies in their animal-health regulatory activities.